Recent studies have centered on the convergence of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and DA neurotransmission. While GCGR stimulators are commonly employed for treating type 2 diabetes, their emerging impacts on reward circuits, specifically influenced by